The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

• DOI: 10.1371/journal.pone.0009499
• Publication Date: 2010-03-02T23:17:58Z
• Authors: Mireia Margeli; Beatriz Cirauqui; Eva Castella; Gustavo Tapia; Carlota Costa; Ana Gimenez-Capitan; Agusti Barnadas; Maria Sanchez Ronco; Susana Benlloch; Miquel Taron; Rafael Rosell
• Keywords: Epirubicin; Neoadjuvant Therapy; Tissue microarray

A fraction of sporadic breast cancers has low BRCA1 expression. mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared non-mutation carriers. Furthermore, ovarian cancer patients levels mRNA have longer survival following platinum-based than high mRNA.Tumor biopsies were obtained from 86 who candidates for neoadjuvant chemotherapy, treated four cycles fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone (PR), HER2, cytokeratin 5/6 vimentin examined by tissue microarray. HER2 also assessed chromogenic in situ hybridization, was analyzed subset 41 whom sufficient tumor available real-time quantitative PCR. Median time progression 42 months overall 55 months. In the multivariate analysis could be assessed, mRNA, positive PR negative lymph node involvement predicted significantly lower risk relapse, only variables associated survival.We provide evidence major role expression as marker anthracycline-based chemotherapy. These findings can useful customizing